Non-Hodgkin lymphoma natural history, complications and prognosis: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Preeti Singh (talk | contribs) |
||
(18 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Non-Hodgkin lymphoma}} | {{Non-Hodgkin lymphoma}} | ||
{{CMG}} | {{CMG}} {{AE}} {{Preeti}} | ||
==Overview== | ==Overview== | ||
Common complications of non-Hodgkin lymphoma include lymphadenopathy, disseminated intravascular coagulation, superior vena cava (SVC) syndrome, [[autoimmune hemolytic anemia]] and [[infection]]. The indolent non-Hodgkin lymphoma types are associated with a relatively good prognosis. The 5-year relative survival rate of patients with NHL is 71.4%. | |||
== Natural History == | |||
==Complications== | |||
Common complications of non-Hodgkin lymphoma include:<ref name="pmid25921177">{{cite journal| author=Dehghani M, Haddadi S, Vojdani R| title=Signs, Symptoms and Complications of Non-Hodgkin's Lymphoma According to Grade and Stage in South Iran. | journal=Asian Pac J Cancer Prev | year= 2015 | volume= 16 | issue= 8 | pages= 3551-7 | pmid=25921177 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25921177 }} </ref> | |||
*[[Lymphadenopathy]] especially cervical [[lymphadenopathy]] | |||
*Cytopenias such as [[neutropenia]], [[anemia]] and [[thrombocytopenia]] secondary to bone marrow infiltration | |||
*[[Autoimmune hemolytic anemia]] | |||
*Bleeding secondary to [[thrombocytopenia]] | |||
*[[Disseminated intravascular coagulation (patient information)|Disseminated intravascular coagulation (DIC)]] | |||
*Infection secondary to [[neutropenia]] | |||
*Cardiac problems secondary to large [[pericardial effusion]] | |||
*[[Cardiac arrhythmias]] secondary to cardiac metastases | |||
*Respiratory problems secondary to [[pleural effusion]] | |||
*[[Superior vena cava (SVC) syndrome]] secondary to a large mediastinal tumor | |||
*Spinal cord compression secondary to vertebral metastases | |||
*Neurologic problems secondary to [[primary CNS lymphoma]] or lymphomatous [[meningitis]] | |||
*Gastrointestinal obstruction, perforation, and bleeding in a patient with [[MALT lymphoma]] | |||
*Pain secondary to [[tumor]] invasion | |||
*[[Lymphocytosis]] in leukemic phase of disease | |||
==Prognosis== | ==Prognosis== | ||
*The 5-year relative survival rate of patients with NHL is 71.4%.<ref name="pmid21224370">{{cite journal| author=Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E et al.| title=Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). | journal=Clin Cancer Res | year= 2011 | volume= 17 | issue= 2 | pages= 346-52 | pmid=21224370 | doi=10.1158/1078-0432.CCR-10-1161 | pmc=4058714 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21224370 }} </ref> | |||
*The survival rate has steadily improved over the last 2 decades, thanks to improvements in medical and nursing care, the advent of novel therapeutic strategies (ie, [[monoclonal antibodies]]), validation of biomarkers of response, and the implementation of tailored treatment. | |||
*The prognosis for patients with NHL depends on the following factors:<ref name="pmid21224370">{{cite journal| author=Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E et al.| title=Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). | journal=Clin Cancer Res | year= 2011 | volume= 17 | issue= 2 | pages= 346-52 | pmid=21224370 | doi=10.1158/1078-0432.CCR-10-1161 | pmc=4058714 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21224370 }} </ref> | |||
**Tumor histology | |||
**Tumor stage | |||
**Patient age | |||
**Tumor bulk | |||
**Performance status | |||
**[[Serum lactate dehydrogenase]] (LDH) level | |||
**[[Beta2-microglobulin]] level | |||
===Prognostic Indexes=== | ===Prognostic Indexes=== | ||
====International Prognostic Index (IPI)==== | ====International Prognostic Index (IPI)==== | ||
The | *The International Prognostic Index (IPI), which was originally designed as a prognostic factor model for aggressive non Hodgkin lymphoma (NHL) appears to be useful for predicting the outcome of patients with low-grade lymphoma and [[mantle cell lymphoma]].<ref name="pmid21224370">{{cite journal| author=Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E et al.| title=Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). | journal=Clin Cancer Res | year= 2011 | volume= 17 | issue= 2 | pages= 346-52 | pmid=21224370 | doi=10.1158/1078-0432.CCR-10-1161 | pmc=4058714 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21224370 }} </ref><ref name="pmid26384083">{{cite journal| author=Shalabi H, Angiolillo A, Vezina G, Rubenstein JL, Pittaluga S, Raffeld M et al.| title=Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System. | journal=Pediatr Hematol Oncol | year= 2015 | volume= 32 | issue= 8 | pages= 529-34 | pmid=26384083 | doi=10.3109/08880018.2015.1074325 | pmc=4942274 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26384083 }} </ref> | ||
*This index is used to identify patients at high risk of relapse, based on specific sites of involvement, including [[Bone marrow abnormality|bone marrow]], [[Brain abscess|CNS]], liver, testis, lung, and spleen. | |||
*Clinical features included in the IPI that are independently predictive of survival include the following: | |||
**Age - Younger than 60 years versus older than 60 years | |||
**LDH level - Within the reference range versus elevated | |||
**Performance status - Eastern Cooperative Oncology Group ( ECOG) grade 0-1 versus 2-4 | |||
**Ann Arbor stage - Stage I-II versus III-IV | |||
**Number of extranodal sites - Zero to 1 versus more than 1 | |||
*With this model, relapse-free and overall survival rates at 5 years are as follows: | |||
== | **0-1 risk factors - 75% | ||
**2-3 risk factors - 50% | |||
**4-5 risk factors - 25% | |||
=== | |||
| | |||
| | |||
| | |||
| | |||
* | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Up-To-Date]] | |||
Latest revision as of 20:44, 21 January 2019
Non-Hodgkin lymphoma Microchapters |
Differentiating Non-Hodgkin's Lymphoma |
---|
Treatment |
Case Studies |
Non-Hodgkin lymphoma natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Non-Hodgkin lymphoma natural history, complications and prognosis |
FDA on Non-Hodgkin lymphoma natural history, complications and prognosis |
CDC on Non-Hodgkin lymphoma natural history, complications and prognosis |
Non-Hodgkin lymphoma natural history, complications and prognosis in the news |
Blogs on Non-Hodgkin lymphoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Overview
Common complications of non-Hodgkin lymphoma include lymphadenopathy, disseminated intravascular coagulation, superior vena cava (SVC) syndrome, autoimmune hemolytic anemia and infection. The indolent non-Hodgkin lymphoma types are associated with a relatively good prognosis. The 5-year relative survival rate of patients with NHL is 71.4%.
Natural History
Complications
Common complications of non-Hodgkin lymphoma include:[1]
- Lymphadenopathy especially cervical lymphadenopathy
- Cytopenias such as neutropenia, anemia and thrombocytopenia secondary to bone marrow infiltration
- Autoimmune hemolytic anemia
- Bleeding secondary to thrombocytopenia
- Disseminated intravascular coagulation (DIC)
- Infection secondary to neutropenia
- Cardiac problems secondary to large pericardial effusion
- Cardiac arrhythmias secondary to cardiac metastases
- Respiratory problems secondary to pleural effusion
- Superior vena cava (SVC) syndrome secondary to a large mediastinal tumor
- Spinal cord compression secondary to vertebral metastases
- Neurologic problems secondary to primary CNS lymphoma or lymphomatous meningitis
- Gastrointestinal obstruction, perforation, and bleeding in a patient with MALT lymphoma
- Pain secondary to tumor invasion
- Lymphocytosis in leukemic phase of disease
Prognosis
- The 5-year relative survival rate of patients with NHL is 71.4%.[2]
- The survival rate has steadily improved over the last 2 decades, thanks to improvements in medical and nursing care, the advent of novel therapeutic strategies (ie, monoclonal antibodies), validation of biomarkers of response, and the implementation of tailored treatment.
- The prognosis for patients with NHL depends on the following factors:[2]
- Tumor histology
- Tumor stage
- Patient age
- Tumor bulk
- Performance status
- Serum lactate dehydrogenase (LDH) level
- Beta2-microglobulin level
Prognostic Indexes
International Prognostic Index (IPI)
- The International Prognostic Index (IPI), which was originally designed as a prognostic factor model for aggressive non Hodgkin lymphoma (NHL) appears to be useful for predicting the outcome of patients with low-grade lymphoma and mantle cell lymphoma.[2][3]
- This index is used to identify patients at high risk of relapse, based on specific sites of involvement, including bone marrow, CNS, liver, testis, lung, and spleen.
- Clinical features included in the IPI that are independently predictive of survival include the following:
- Age - Younger than 60 years versus older than 60 years
- LDH level - Within the reference range versus elevated
- Performance status - Eastern Cooperative Oncology Group ( ECOG) grade 0-1 versus 2-4
- Ann Arbor stage - Stage I-II versus III-IV
- Number of extranodal sites - Zero to 1 versus more than 1
- With this model, relapse-free and overall survival rates at 5 years are as follows:
- 0-1 risk factors - 75%
- 2-3 risk factors - 50%
- 4-5 risk factors - 25%
References
- ↑ Dehghani M, Haddadi S, Vojdani R (2015). "Signs, Symptoms and Complications of Non-Hodgkin's Lymphoma According to Grade and Stage in South Iran". Asian Pac J Cancer Prev. 16 (8): 3551–7. PMID 25921177.
- ↑ 2.0 2.1 2.2 Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E; et al. (2011). "Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)". Clin Cancer Res. 17 (2): 346–52. doi:10.1158/1078-0432.CCR-10-1161. PMC 4058714. PMID 21224370.
- ↑ Shalabi H, Angiolillo A, Vezina G, Rubenstein JL, Pittaluga S, Raffeld M; et al. (2015). "Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System". Pediatr Hematol Oncol. 32 (8): 529–34. doi:10.3109/08880018.2015.1074325. PMC 4942274. PMID 26384083.